Welcome to our dedicated page for Twist Bioscience SEC filings (Ticker: TWST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Twist Bioscience Corporation filings document formal disclosures for a synthetic biology company with a silicon-based DNA synthesis platform. Form 8-K reports furnish quarterly and annual financial results, preliminary revenue information and business highlights tied to products and services such as synthetic DNA, NGS workflow tools and antibody discovery solutions.
The filing record also covers unregistered common stock issuances connected to licensing and technology-transfer arrangements, annual meeting voting results, director elections, auditor ratification, executive compensation votes, board appointments, committee service and director compensation. These disclosures address governance, capital structure and material events for TWST common stock.
Form 4 overview: On 06/16/2025, Twist Bioscience Corporation (TWST) officer Dennis Cho executed a mandatory “sell-to-cover” transaction, disposing of 94 common shares at $33.475 per share to satisfy tax-withholding obligations arising from vested Restricted Stock Units. This was not a discretionary trade under Rule 10b5-1.
After the sale, Cho continues to beneficially own 104,967 TWST shares and remains Senior Vice President, Chief Legal Officer & Corporate Secretary. The divestiture represents well under 0.1 % of his holdings, leaving insider ownership essentially unchanged and providing limited informational value for investors.